Evidence map›Paper›PMID 35264675›Full record

ArticleScientific reports2022

Genetic association of IL17 and the importance of ABO blood group antigens in saliva to COVID-19.

Nao Nishida, Masaya Sugiyama, Yosuke Kawai, Izumi Naka, Noriko Iwamoto, Tetsuya Suzuki, Michiyo Suzuki, Yusuke Miyazato, Satoshi Suzuki, Shinyu Izumi and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Detection of c.375A>G, c.385A>T, c.571C>T, andDiagnostics (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Hallmarks of Severe COVID-19 Pathogenesis:Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Nao NishidaGenome Medical Science Project, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Chiba, Ichikawa, 272-8516, Japan. lb-naonishida@hospk.ncgm.go.jp.
Masaya SugiyamaGenome Medical Science Project, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Chiba, Ichikawa, 272-8516, Japan.
Yosuke KawaiGenome Medical Science Project, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, 162-8655, Japan.
Izumi NakaDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Noriko IwamotoDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Shinjuku-ku, Tokyo, 162-8655, Japan.
Tetsuya SuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Shinjuku-ku, Tokyo, 162-8655, Japan.
Michiyo SuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Shinjuku-ku, Tokyo, 162-8655, Japan.
Yusuke MiyazatoDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Shinjuku-ku, Tokyo, 162-8655, Japan.
Satoshi SuzukiBiobank, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, 162-8655, Japan.
Shinyu IzumiDepartment of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Shinjuku-ku, Tokyo, 162-8655, Japan.
Masayuki HojoDepartment of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Shinjuku-ku, Tokyo, 162-8655, Japan.
Takayo TsuchiuraGenome Medical Science Project, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Chiba, Ichikawa, 272-8516, Japan.
Miyuki IshikawaGenome Medical Science Project, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Chiba, Ichikawa, 272-8516, Japan.
Jun OhashiDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Shinjuku-ku, Tokyo, 162-8655, Japan.
Katsushi TokunagaGenome Medical Science Project, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, 162-8655, Japan.
Masashi MizokamiGenome Medical Science Project, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Chiba, Ichikawa, 272-8516, Japan.
National Center for Global Health and Medicine · JPThe University of Tokyo · JP

Funding

Japan Agency for Medical Research and Development JP20fk0108104Japan Agency for Medical Research and Development JP20fk0108164Japan Agency for Medical Research and Development JP21km0405501Japan Society for the Promotion of Science JP21K06357National Center for Global Health and Medicine 20A2002DNational Center for Global Health and Medicine 20A2009
6 · The paper itself

Abstract

The outbreak of COVID-19 caused by infection with SARS-CoV-2 virus has become a worldwide pandemic, and the number of patients presenting with respiratory failure is rapidly increasing in Japan. An international meta-analysis has been conducted to identify genetic factors associated with the onset and severity of COVID-19, but these factors have yet to be fully clarified. Here, we carried out genomic analysis based on a genome-wide association study (GWAS) in Japanese COVID-19 patients to determine whether genetic factors reported to be associated with the onset or severity of COVID-19 in the international meta-GWAS are replicated in the Japanese population, and whether new genetic factors exist. Although no significant genome-wide association was detected in the Japanese GWAS, an integrated analysis with the international meta-GWAS identified for the first time the involvement of the IL17A/IL17F gene in the severity of COVID-19. Among nine genes reported in the international meta-GWAS as genes involved in the onset of COVID-19, the association of FOXP4-AS1, ABO, and IFNAR2 genes was replicated in the Japanese population. Moreover, combined analysis of ABO and FUT2 genotypes revealed that the presence of oral AB antigens was significantly associated with the onset of COVID-19. FOXP4-AS1 and IFNAR2 were also significantly associated in the integrated analysis of the Japanese GWAS and international meta-GWAS when compared with severe COVID-19 cases and the general population. This made it clear that these two genes were also involved in not only the onset but also the severity of COVID-19. In particular, FOXP4-AS1 was not found to be associated with the severity of COVID-19 in the international meta-GWAS, but an integrated analysis with the Japanese GWAS revealed an association with severity. Individuals with the SNP risk allele found between IL17A and IL17F had significantly lower mRNA expression levels of IL17F, suggesting that activation of the innate immune response by IL17F may play an important role in the severity of SARS-CoV-2 infection.

Indexed as

ABO Blood-Group SystemAdultAgedAged, 80 and overAllelesCOVID-19FemaleGenome-Wide Association StudyHumansInterleukin-17JapanMaleMiddle AgedPolymorphism, Single NucleotideRisk FactorsSalivaABO Blood-Group SystemIL17A protein, humanIL17F protein, humanInterleukin-17

Identifiers

PMID35264675
PMCPMC8907215
OpenAlexW4220803812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.